Dr. Bob schreef op 31 maart 2020 10:41:
In de guidance van 21 februari 2020 staat geschreven:
today announced that unblinding of the Phase 3 RESOLVE-IT data will be delayed to incorporate the latest FDA insights expected by the end of March. Op 31 maart 2020 staat geschreven:
The un-blinding of the study and subsequent announcement of interim results will take place after receipt and incorporation of insight from the FDA. We do not currently anticipate that the COVID-19 situation will significantly delay receipt of this feedback. Key lijkt mij de waarde die we aan het woord
'significant' mogen toedichten.
ir.genfit.com/news-releases/news-rele...